Bharat Serums and Vaccines Limited, a biopharmaceutical company, researches, develops, manufactures, and markets injectable biological, pharmaceutical, and biotechnology products. Its products portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anesthetics, cardiovascular drugs, and equine immunoglobulins/antitoxins. The company also engages in the research and development of drug delivery systems, biotechnology/recombinant therapeutics, and biological/equine products; development of recombinant molecules, such as cell lines and lab scale processes for biosimilar products; and research, development, and manufacture of therapeutic proteins. In addition, it offers products in the areas of gynecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, hematology, and urology. The company provides its products to retail outlets and hospitals through distributors primarily in India, as well as in the Asia Pacific, the Russian Federation, CIS countries, Latin America, Africa, and internationally. Bharat Serums and Vaccines Limited was founded in 1971 and is headquartered in Thane, India with liaison offices in the Russian Federation, the Philippines, Vietnam, Nigeria, and Ukraine. It has manufacturing facilities in Ambernath and Ahmedabad, India, as well as in Aachen, Germany; and research and development facilities in India, Germany, and the United States. As of February 29, 2020, Bharat Serums and Vaccines Limited operates as a subsidiary of Ansamira Limited.